SCHEDULE 13G/A: Citadel Entities Disclose 3.9% Passive Stake in Korro Bio, Inc.
Beneficial Ownership Disclosure
Citadel Advisors LLC and affiliated entities, including Kenneth Griffin, have filed an amended Schedule 13G disclosing a 3.9% beneficial ownership stake in Korro Bio, Inc. as of December 31, 2024.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin collectively reported beneficial ownership of 369,733 shares of Korro Bio, Inc. Common Stock.
- This ownership represents 3.9% of Korro Bio, Inc.'s outstanding shares, based on 9,368,262 shares outstanding as of November 7, 2024, as reported in the issuer's Form 10-Q.
- The reporting persons, including Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, and Kenneth Griffin, share both voting and dispositive power over these 369,733 shares.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC reported 0 shares beneficially owned.
- The filing is an Amendment No. 2 to a previously filed Schedule 13G, indicating an update to their ownership disclosure.
- The shares are held for investment purposes and not with the intent to change or influence the control of Korro Bio, Inc., consistent with a passive investment.
- The principal executive offices of Korro Bio, Inc. are located at 60 First Street 2nd Floor, Suite 250 Cambridge, MASSACHUSETTS, 02141.
- The principal business office of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of passive beneficial ownership by a major investment firm in a publicly traded company, common in the financial industry for compliance with SEC regulations.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant passive ownership stake by Citadel entities, confirming their investment position in Korro Bio, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-11-07 | Date as of which Korro Bio, Inc. had 9,368,262 Shares outstanding, according to its Form 10-Q. |
| 2024-11-12 | Date Korro Bio, Inc.'s Form 10-Q was filed with the SEC. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end). |
| 2025-02-14 | Date of filing of this Schedule 13G Amendment No. 2. |
Keywords
Korro Bio Inc., Citadel Advisors LLC, Kenneth Griffin, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.